Drug Search Results
More Filters [+]

Doravirine

Alternative Names: doravirine, mk-1439, pifeltro, mk1439, mk 1439, delstrigo
Latest Update: 2024-09-02
Latest Update Note: Clinical Trial Update

Product Description

Doravirine (brand name: Pifeltro) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults who meet certain requirements, as determined by a health care provider. Doravirine is always used in combination with other HIV medicines. (Sourced from: https://clinicalinfo.hiv.gov/en/drugs/doravirine/patient)

Mechanisms of Action: NNRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: HIV Infections | HIV Infections

Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Diarrhea

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doravirine

Countries in Clinic: Argentina, Australia, Brazil, Cambodia, Cameroon, Canada, Chile, Colombia, Finland, France, Germany, Israel, Italy, Ivory Coast, Japan, Korea, Malaysia, Mexico, Mozambique, Netherlands, New Zealand, Peru, Poland, Portugal, Puerto Rico, Russia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Communicable Diseases|HIV Infections

Phase 2: Acquired Immunodeficiency Syndrome

Phase 1: Healthy Volunteers|Lipid Metabolism Disorders|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-1439-066

P2

Recruiting

HIV Infections|Acquired Immunodeficiency Syndrome

2028-03-04

25%

ANRS0392s ELDORADO

P3

Not yet recruiting

HIV Infections

2027-09-01

jRCT2031220720

P3

Recruiting

HIV Infections

2026-08-03

MK-8591A-053

P3

Recruiting

HIV Infections

2026-08-01

Recent News Events